ISRCTN10324656
Active, not recruiting
Phase 4
Beta-blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP): a blinded, multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Participants with cirrhosis and small varices without evidence of previous bleeding
- Sponsor
- King’s College Hospital NHS Foundation Trust
- Enrollment
- 763
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35113923/ results of the embedded qualitative study (added 04/02/2022) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36251653/ results of the embedded qualitative study (added 18/10/2022) 2024 Protocol article in https://doi.org/10.1186/s13063-024-08063-3 (added 17/04/2024)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age \>18 years
- •2\. Cirrhosis and portal hypertension, defined by any two of the following:
- •2\.1\. Characteristic clinical examination findings; one or more of:
- •2\.1\.1\. Jaundice, ascites, caput medusae, spider naevi, palmar erythema, asterixis
- •2\.2\. Characteristic liver function tests, haematological panel and coagulation profile abnormalities
- •2\.2\.1\. hyperbilirubinaemia (serum total bilirubin \> 30 umol/l)
- •2\.2\.2\. thrombocytopenia (platelet count \<120 x109 / L)
- •2\.2\.3\.international normalised raio (INR) \> 1\.5
- •NB These blood tests may be normal in well compensated cirrhosis – if cirrhosis is confirmed on other investigations, normal blood tests suggest well compensated disease.
- •2\.3\. Characteristic radiological findings; one or more of:
Exclusion Criteria
- •1\. Non\-cirrhotic portal hypertension
- •2\. Medium/large oesophageal varices (current or history of)
- •3\. Isolated gastric, duodenal, rectal varices with or without evidence of recent bleeding
- •4\. Previous variceal haemorrhage
- •5\. Known intolerance to beta blockers
- •6\. Contraindication to beta blocker use:
- •6\.1\. Heart rate \<50 bpm
- •6\.2\. Known 2nd degree or higher heart block
- •6\.3\. Sick sinus syndrome
- •6\.4\. Systolic blood pressure \<85mm Hg
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Comparing Carvedilol versus Placebo on the rate of variceal haemorrhage in patients with cirrhosis of the liver and small oesophageal varicesiver cirrhosis with small oesophageal varicesMedDRA version: 20.0Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871MedDRA version: 21.1Level: LLTClassification code 10055489Term: Esophageal varices in cirrhosis of liverSystem Organ Class: 100000004856Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]EUCTR2018-002509-78-GBKings College Hospital NHS Foundation Trust1,200
Unknown
Not Applicable
Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary SyndromeActue Coronary SyndromeNCT03658577Shenzhen People's Hospital582
Terminated
Phase 3
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02587351University of Minnesota532
Completed
Not Applicable
Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)CirrhosisNCT00772057Govind Ballabh Pant Hospital164
Completed
Not Applicable
Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysisPheochromocytomaNCT04557072Jagiellonian University1,344